Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Veterinary Intravenous (IV) Solutions Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The veterinary intravenous (iv) solutions market size has exhibited strong growth in recent years. This market is set to expand from $1.62 billion in 2025 to $1.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. The increase observed in the past can be attributed to several factors including the rising prevalence of dehydration and electrolyte imbalances in animals, an expanding companion animal population, the growing number of veterinary hospitals and clinics, the adoption of conventional IV solutions, and technological advancements within veterinary fluid therapy.
The veterinary intravenous (iv) solutions market is projected to experience substantial expansion in the coming years. This market is set to reach $2.36 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This anticipated growth is driven by several factors, including the increasing demand for sophisticated isotonic and colloid solutions, the greater use of parenteral nutrition in animal healthcare, the creation of specific IV solutions for critical care scenarios, a heightened understanding of the advantages of fluid therapy, and the expansion of veterinary emergency and critical care provisions. Key trends anticipated during this period encompass the innovation of advanced isotonic and balanced electrolyte solutions, a rise in the application of both synthetic and natural colloids, an increase in parenteral nutrition solutions tailored for companion and production animals, the uptake of pre-mixed and ready-to-use IV solutions, and the broadening of veterinary critical care and emergency fluid therapy services.
Get A Free Sample Report With In-Depth Market Insights:
Veterinary Intravenous (IV) Solutions Market Expansion Drivers: What’s Shaping Future Growth?
The rising occurrence of various animal illnesses is anticipated to stimulate the expansion of the Veterinary Intravenous (IV) Solutions Market moving forward. Animal diseases are defined as conditions or health issues that negatively impact an animal’s well-being and bodily functions. Common examples include anthrax, leptospirosis, rabies, canine distemper, and heartworm disease. This surge in animal disease prevalence is influenced by factors such as intensive farming practices, wildlife encroachment, and increasing antibiotic resistance. Veterinary intravenous solutions are vital for rehydrating animals suffering from dehydration-inducing conditions, such as gastroenteritis or severe infections, by ensuring optimal fluid balance and supporting overall health outcomes. For instance, in May 2025, the World Organisation for Animal Health (WOAH), a France-based intergovernmental animal health body, reported that outbreaks of avian influenza in mammals more than doubled last year compared with 2023, with 1,022 reported outbreaks across 55 countries, up from 459 outbreaks in 2023, indicating a significant rise in disease prevalence across multiple species. Thus, the increased prevalence of diverse animal diseases is a key driver for the growth of the Veterinary Intravenous (IV) Solutions Market.
Veterinary Intravenous (IV) Solutions Market Segment Analysis Spotlighting Growth Areas
The veterinary intravenous (iv) solutions market covered in this report is segmented –
1) By Product: Isotonic Crystalloids, Dextrose Solutions, Synthetic Colloids, Natural Colloids, Parenteral Nutrition
2) By Animal Type: Companion Animals, Production Animals
3) By End-User: Veterinary Hospitals And Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Isotonic Crystalloids: Normal Saline (0.9% NaCl), Lactated Ringer’s Solution, Dextrose In Water (D5W), Ringer’s Solution, Balanced Electrolyte Solutions
2) By Dextrose Solutions: Dextrose 5% In Water (D5W), Dextrose 10% In Water (D10W), Dextrose 20% In Water (D20W), Dextrose 50% In Water (D50W)
3) By Synthetic Colloids: Hydroxyethyl Starch (HES), Dextran, Gelatins
4) By Natural Colloids: Albumin, Fresh Frozen Plasma (FFP), Blood Products
5) By Parenteral Nutrition: Total Parenteral Nutrition (TPN) Solutions, Partial Parenteral Nutrition Solutions, Lipid Emulsions, Amino Acid Solutions
Veterinary Intravenous (IV) Solutions Market Strategic Trends: What Defines The Next Growth Phase?
Major companies operating in the veterinary intravenous (IV) solutions market are concentrating on the development of advanced products, such as fluoroquinolone, to enhance their effectiveness and safety profiles. Fluoroquinolones constitute a powerful category of antibiotics employed in both human and veterinary medicine for treating various bacterial infections, which need careful management to reduce the potential for resistance and adverse reactions. For instance, in April 2024, Elanco, a pharmaceutical company situated in the US, introduced Pradalex, a pradofloxacin injection solution that received approval from the US Food and Drug Administration (FDA), a US-based health organization. The authorization for swine pertains to managing swine respiratory disease (SRD) linked to bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, streptococcus suis, and mycoplasma hyopneumoniae. Pradalex is a third-generation fluoroquinolone, recognized as a critically important antimicrobial. The drug’s instructions stipulate that it should be administered only after evaluating other therapeutic options that do not involve fluoroquinolones.
Veterinary Intravenous (IV) Solutions Market Key Players Shaping Industry Direction
Major companies operating in the veterinary intravenous (iv) solutions market are Merck & Co. Inc., Baxter International Inc., Zoetis Inc., Fresenius Kabi AG, Elanco Animal Health Incorporated, B. Braun Melsungen AG, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol SA, Norbrook Laboratories Limited, Ceva Santé Animale, Revival Animal Health Inc., Aromor Animal Health, Jorgensen Laboratories LLC, Pharmacosmos AS, Sykes Veterinary International Pty Ltd., Rusoma Laboratories Private Limited, Patterson Companies Inc., NexGen Veterinary, Soxa Formulations & Research Pvt. Ltd
View The Full Veterinary Intravenous (IV) Solutions Market Report:
Veterinary Intravenous (IV) Solutions Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the veterinary intravenous (IV) solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary intravenous (iv) solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
